In response to the 2019 Novel Coronavirus outbreak, the federal government is taking steps to protect the country. Within the U.S. Department of Health and Human Services, the Office of the Assistant Secretary for Preparedness and Response is working with our partners to explore the development of new medical countermeasures and take other actions to enhance health security.
Monoclonal Antibody Therapeutics
The FDA has issued Emergency Use Authorizations for three investigational monoclonal antibody treatments. These treatments have been authorized for patients with mild to moderate cases: those who have had symptoms for 10 days or less, who are 12 years and older, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes people who are 65 years old or older, and who have certain chronic medical conditions. Find out what infusion site professionals patients, and healthcare providers need to know about monoclonal antibody therapeutics.
  |
  |
  |
Comments
0 comments
Please sign in to leave a comment.